RxDoctor Payments DataLook up a doctor →

Mark Box, MD

Rheumatology · Kansas City, MONPI 1477604817

Payments from drug & device makers

$395,831in general payments, 2019–2025

Across 2,054 payments — averaging $192.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$132K
  • AbbVie$56K
  • GSK$53K
  • AstraZeneca$41K
  • Amgen$38K
  • E.r. Squibb & Sons, L.L.C.$16K
  • plus $59K from 54 others

What the payments were for

  • Consulting fees$28,0739%
  • Speaking & faculty fees$207,48668%
  • Travel & lodging$28,3979%
  • Food & beverage$39,19213%
  • Education$6140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer272$132,250
AbbVie336$55,777
GSK128$53,480
AstraZeneca(2 entities)108$40,842
Amgen(2 entities)414$37,690
E.r. Squibb & Sons, L.L.C.69$16,449
Novartis72$13,410
Sanofi38$6,123
Mallinckrodt Enterprises LLC15$5,710
Gilead15$5,469
Genentech USA, Inc.45$5,089
Regeneron Healthcare Solutions, Inc.12$3,458
Janssen Scientific Affairs, LLC10$3,296
UCB, Inc.69$2,908
Johnson & Johnson(3 entities)132$2,640
Janssen Global Services, LLC1$2,000
Fresenius Kabi USA, LLC13$1,806
Lilly USA, LLC87$1,589
Boehringer Ingelheim13$1,343
Mallinckrodt Hospital Products Inc.32$805
ANI Pharmaceuticals, Inc.33$624
Aurinia Pharma U.S., Inc.17$488
Actelion Pharmaceuticals US, Inc.10$222
Organon14$201
Hospira, Inc.12$199
United Therapeutics Corporation7$193
Sanofi-aventis U.S. LLC8$171
Tersera Therapeutics LLC5$125
Sobi, Inc2$125
Collegium Pharmaceutical, Inc.7$124
Ultragenyx Pharmaceutical Inc.5$94
Sandoz4$90
Kyowa Kirin, Inc.2$84
Radius Health, Inc.5$82
Genentech, Inc.1$82
Kiniksa Pharmaceuticals, Ltd.1$77
Grifols USA, LLC3$71
Kiniksa Pharmaceuticals International, PLC3$58
Invivyd Inc3$57
Novo Nordisk3$52
Bioventus LLC2$45
Mylan Institutional Inc.2$44
Octapharma USA, Inc.2$34
Eisai Inc.2$30
Antares Pharma, Inc.2$29
Takeda Pharmaceuticals U.S.A., Inc.2$28
Ironwood Pharmaceuticals, Inc2$27
Bristol Myers Squibb1$23
Pacira Therapeutics, Inc.2$23
Teva Pharmaceuticals USA, Inc.1$22
Vertex1$22
Upsher-smith Laboratories LLC1$19
Celltrion USA Inc.1$19
Daiichi Sankyo Inc.1$18
Almatica Pharma LLC1$18
Tonix Medicines, Inc.1$17
Idorsia Pharmaceuticals US Inc1$16
Boston Scientific1$15
Medexus Pharma, Inc.1$12
Fidia Pharma USA Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$395,831 in reported general payments places this provider in the 90th percentile of 134 rheumatology providers in Missouri.

See all rheumatology providers in Missouri

Medicare billing

Part B allowed, 2024
$2,919,661
Medicare patients
523
Services billed
177,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab27$338,870
Enbrel SureclickEtanercept26$234,133
Orencia ClickjectAbatacept21$158,479
Xeljanz XrTofacitinib Citrate21$132,677
Cosentyx Sensoready (2 Pens)Secukinumab18$122,778
Enbrel MiniEtanercept14$101,831
RinvoqUpadacitinib14$91,058
Humira(Cf)Adalimumab11$88,408
BenlystaBelimumab31$85,431
OxycontinOxycodone Hcl47$46,078
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen654$22,988
Hydroxychloroquine Sulfate355$18,471
LinzessLinaclotide24$16,578
Mycophenolate Mofetil119$15,983
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen344$14,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf), Linzess, Restasis, Lexapro$55,777$214,35684 claims
GSKBenlysta$53,480$85,43131 claims
Upsher-smith Laboratories LLCTopiramate$19$2,071101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 134 rheumatology providers in Missouri.

Other rheumatology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →